Skip to main content
Erschienen in: Lung 6/2018

27.08.2018 | INTERSTITIAL LUNG DISEASE

Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity

verfasst von: Hana Serajeddini, Paola Rogliani, Marco Mura

Erschienen in: Lung | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose

The pathophysiology of idiopathic pulmonary fibrosis (IPF) is complex, and its clinical course is difficult to predict. Perceived dyspnea, exercise capacity, and lung physiology have all been associated with mortality outcomes in IPF, but the significance of these relationships is unclear. We sought to investigate the correlation among these variables and their independent predictive capability in determining mortality outcomes.

Methods

Four-hundred-thirty-seven patients diagnosed with IPF from three independent centers were included in the study. Medical Research Council Dyspnea Score (MRCDS), 6-min walk distance (6MWD), and pulmonary function tests were determined at baseline. The end-point was 18-month transplant-free survival.

Results

Correlations between MRCDS, 6MWD, forced vital capacity (FVC), and diffusing lung capacity for carbon monoxide were either very weak or weak. Calculation of variance inflation factors demonstrated absence of collinearity among these variables. Univariate regression analysis and c-statistics identified MRCDS, 6MWD, and FVC as significant predictors of 18-month transplant-free survival. Multivariate regression analysis retained MRCDS, 6MWD, and FVC as independent predictors of mortality. To ensure generalizability, we confirmed the results in subgroups of patients stratified according to baseline FVC, and further by considering lung transplant as a competing event to death.

Conclusions

In a cohort of patients with IPF encompassing a wide range of disease severity, baseline perceived exertional dyspnea, exercise capacity, and lung function are weakly correlated to each other, translating in the absence of collinearity. MRCDS, 6MWD, and FVC are significant and independent predictors of outcome, suggesting that a multi-dimensional assessment of IPF is prognostically appropriate and advantageous.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRef Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011) An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183:788–824CrossRef
2.
Zurück zum Zitat Ley B, Collard HR, King TE Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183:431–440CrossRef Ley B, Collard HR, King TE Jr (2011) Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 183:431–440CrossRef
3.
Zurück zum Zitat Mura M, Ferretti A, Ferro O, Zompatori M, Cavalli A, Schiavina M, Fabbri M (2006) Functional predictors of exertional dyspnoea, 6 min walking distance and HRCT fibrosis score in idiopathic pulmonary fibrosis. Respiration 73:495–502CrossRef Mura M, Ferretti A, Ferro O, Zompatori M, Cavalli A, Schiavina M, Fabbri M (2006) Functional predictors of exertional dyspnoea, 6 min walking distance and HRCT fibrosis score in idiopathic pulmonary fibrosis. Respiration 73:495–502CrossRef
4.
Zurück zum Zitat du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr (2011) Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 183:1231–1237CrossRef du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, Lancaster L, Noble PW, Sahn SA, Szwarcberg J, Thomeer M, Valeyre D, King TE Jr (2011) Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 183:1231–1237CrossRef
5.
Zurück zum Zitat Khadawardi H, Mura M (2017) A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease. Respirology 22:501–507CrossRef Khadawardi H, Mura M (2017) A simple dyspnoea scale as part of the assessment to predict outcome across chronic interstitial lung disease. Respirology 22:501–507CrossRef
6.
Zurück zum Zitat du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr (2014) 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 43:1421–1429CrossRef du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, Noble PW, Sahn SA, Valeyre D, Weycker D, King TE Jr (2014) 6-minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis. Eur Respir J 43:1421–1429CrossRef
7.
Zurück zum Zitat King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092CrossRef King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092CrossRef
8.
Zurück zum Zitat Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU (2016) Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: Analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 71:429–435CrossRef Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE Jr, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU (2016) Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: Analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax 71:429–435CrossRef
9.
Zurück zum Zitat Hosein K, Le J, Mura M (2016) Assessing the therapeutic response to pirfenidone in idiopathic pulmonary fibrosis: can we do better than with forced vital. Capacity Alone? Lung 195:101–105CrossRef Hosein K, Le J, Mura M (2016) Assessing the therapeutic response to pirfenidone in idiopathic pulmonary fibrosis: can we do better than with forced vital. Capacity Alone? Lung 195:101–105CrossRef
10.
Zurück zum Zitat Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ (2004) Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 170:904–910CrossRef Flaherty KR, King TE Jr, Raghu G, Lynch JP 3rd, Colby TV, Travis WD, Gross BH, Kazerooni EA, Toews GB, Long Q, Murray S, Lama VN, Gay SE, Martinez FJ (2004) Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med 170:904–910CrossRef
11.
Zurück zum Zitat Mahler DA, Jones PW, Guyatt GH (1998) Clinical measurement of dyspnoea. In: Mahler DA (ed) Dyspnoea. Marcel Dekker, New York, pp 149–198 Mahler DA, Jones PW, Guyatt GH (1998) Clinical measurement of dyspnoea. In: Mahler DA (ed) Dyspnoea. Marcel Dekker, New York, pp 149–198
12.
Zurück zum Zitat ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117CrossRef
13.
Zurück zum Zitat American Thoracic Society (1995) Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152:1107–1136CrossRef American Thoracic Society (1995) Standardization of spirometry, 1994 update. Am J Respir Crit Care Med 152:1107–1136CrossRef
14.
Zurück zum Zitat Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158:1384–1387CrossRef Enright PL, Sherrill DL (1998) Reference equations for the six-minute walk in healthy adults. Am J Respir Crit Care Med 158:1384–1387CrossRef
15.
Zurück zum Zitat Oztuna D, Elhan AH, Tuccar E (2006) Investigation of four different normality tests in terms of type 1 error rate and power under different distributions. Turk J Med Sci 36:171–176 Oztuna D, Elhan AH, Tuccar E (2006) Investigation of four different normality tests in terms of type 1 error rate and power under different distributions. Turk J Med Sci 36:171–176
16.
Zurück zum Zitat Myers JL, Well AD, Lorch RF (2003) Research design and statistical analysis, 2nd edn. Lawrence Erlbaum, Hillsdale Myers JL, Well AD, Lorch RF (2003) Research design and statistical analysis, 2nd edn. Lawrence Erlbaum, Hillsdale
17.
Zurück zum Zitat Slinker BY, Glantz SA (1985) Multiple regression for physiological data analysis: the problem of multicollinearity. Am J Phys 249:R1–R12CrossRef Slinker BY, Glantz SA (1985) Multiple regression for physiological data analysis: the problem of multicollinearity. Am J Phys 249:R1–R12CrossRef
18.
Zurück zum Zitat DeLong ER, DeLong DL, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845CrossRef DeLong ER, DeLong DL, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845CrossRef
19.
Zurück zum Zitat Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496–509CrossRef
20.
Zurück zum Zitat Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ (2004) The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350:1005–1012CrossRef Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ (2004) The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350:1005–1012CrossRef
21.
Zurück zum Zitat Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382CrossRef Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, Lewis SA, Macfarlane JT (2003) Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 58:377–382CrossRef
22.
Zurück zum Zitat Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P (2012) Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 40:101–109CrossRef Mura M, Porretta MA, Bargagli E, Sergiacomi G, Zompatori M, Sverzellati N, Taglieri A, Mezzasalma F, Rottoli P, Saltini C, Rogliani P (2012) Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J 40:101–109CrossRef
23.
Zurück zum Zitat Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S (2010) A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 36:1067–1072CrossRef Nishiyama O, Taniguchi H, Kondoh Y, Kimura T, Kato K, Kataoka K, Ogawa T, Watanabe F, Arizono S (2010) A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 36:1067–1072CrossRef
24.
Zurück zum Zitat Manali ED1, Stathopoulos GT, Kollintza A, Kalomenidis I, Emili JM, Sotiropoulou C, Daniil Z, Roussos C, Papiris SA (2008) The Medical Research Council chronic dyspnoea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir Med 102:586–592CrossRef Manali ED1, Stathopoulos GT, Kollintza A, Kalomenidis I, Emili JM, Sotiropoulou C, Daniil Z, Roussos C, Papiris SA (2008) The Medical Research Council chronic dyspnoea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir Med 102:586–592CrossRef
25.
Zurück zum Zitat Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171:1150–1157CrossRef Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 171:1150–1157CrossRef
26.
Zurück zum Zitat Dowman LM, McDonald CF, Bozinovski S, Vlahos R, Gillies R, Pouniotis D, Hill CJ, Goh NSL, Holland AE (2017) Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia. Respirology 22:957–964CrossRef Dowman LM, McDonald CF, Bozinovski S, Vlahos R, Gillies R, Pouniotis D, Hill CJ, Goh NSL, Holland AE (2017) Greater endurance capacity and improved dyspnoea with acute oxygen supplementation in idiopathic pulmonary fibrosis patients without resting hypoxaemia. Respirology 22:957–964CrossRef
27.
Zurück zum Zitat Glaspole IN, Watson AL, Allan H, Chapman S, Cooper WA, Corte TJ, Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y, Reynolds PN, Ryerson CJ, Walters EH, Zappala CJ, Holland AE (2017) Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. Eur Respir J 50:1700168CrossRef Glaspole IN, Watson AL, Allan H, Chapman S, Cooper WA, Corte TJ, Ellis S, Grainge C, Goh N, Hopkins P, Keir G, Macansh S, Mahar A, Moodley Y, Reynolds PN, Ryerson CJ, Walters EH, Zappala CJ, Holland AE (2017) Determinants and outcomes of prolonged anxiety and depression in idiopathic pulmonary fibrosis. Eur Respir J 50:1700168CrossRef
28.
Zurück zum Zitat Troy LK, Young IH, Lau EMT, Corte TJ (2016) Exercise pathophysiology and the role of oxygen therapy in idiopathic interstitial pneumonia. Respirology 21:1005–1014CrossRef Troy LK, Young IH, Lau EMT, Corte TJ (2016) Exercise pathophysiology and the role of oxygen therapy in idiopathic interstitial pneumonia. Respirology 21:1005–1014CrossRef
29.
Zurück zum Zitat Rinaldi S, Mura M, Madill J (2017) Interstitial lung disease, body mass index, energy expenditure and malnutrition—a review. Curr Pulmonol Rep 6:70–74CrossRef Rinaldi S, Mura M, Madill J (2017) Interstitial lung disease, body mass index, energy expenditure and malnutrition—a review. Curr Pulmonol Rep 6:70–74CrossRef
30.
Zurück zum Zitat Minai O, Santacruz JF, Alster JM, Budev MM, McCarthy K (2012) Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med 106:1613–1621CrossRef Minai O, Santacruz JF, Alster JM, Budev MM, McCarthy K (2012) Impact of pulmonary hemodynamics on 6-min walk test in idiopathic pulmonary fibrosis. Respir Med 106:1613–1621CrossRef
31.
Zurück zum Zitat Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S (2009) Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 103:117–123CrossRef Caminati A, Bianchi A, Cassandro R, Mirenda MR, Harari S (2009) Walking distance on 6-MWT is a prognostic factor in idiopathic pulmonary fibrosis. Respir Med 103:117–123CrossRef
32.
Zurück zum Zitat Yorke J, Swigris J, Russell AM, Moosavi SH, Ng Man Kwong G, Longshaw M, Jones PW (2011) Dyspnoea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest 139:159–164CrossRef Yorke J, Swigris J, Russell AM, Moosavi SH, Ng Man Kwong G, Longshaw M, Jones PW (2011) Dyspnoea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest 139:159–164CrossRef
33.
Zurück zum Zitat Altman DG (1991) Statistics in medical journals: developments in the 1980s. Stat Med 10:1897–1913CrossRef Altman DG (1991) Statistics in medical journals: developments in the 1980s. Stat Med 10:1897–1913CrossRef
34.
Zurück zum Zitat Glantz SA, Slinker BY (2001) Applied regression and analysis of variance. McGraw-Hill, New York Glantz SA, Slinker BY (2001) Applied regression and analysis of variance. McGraw-Hill, New York
35.
Zurück zum Zitat Maddala GS (2001) Multicollinearity. In: Maddala GS (ed) Introduction to econometrics. Wiley, New York, pp 267–300 Maddala GS (2001) Multicollinearity. In: Maddala GS (ed) Introduction to econometrics. Wiley, New York, pp 267–300
Metadaten
Titel
Multi-dimensional Assessment of IPF Across a Wide Range of Disease Severity
verfasst von
Hana Serajeddini
Paola Rogliani
Marco Mura
Publikationsdatum
27.08.2018
Verlag
Springer US
Erschienen in
Lung / Ausgabe 6/2018
Print ISSN: 0341-2040
Elektronische ISSN: 1432-1750
DOI
https://doi.org/10.1007/s00408-018-0152-4

Weitere Artikel der Ausgabe 6/2018

Lung 6/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.